SCHEMBL948715

SCHEMBL948715

C=CCOC(=O)CCS(=O)(=O)c1cc2cc(Cl)ccc2n1C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NR1H2 P55055 9/20 0.34
ALDH1A1 P00352 3/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 2/20 0.32
PPARA Q07869 2/20 0.32
F13A1 P00488 1/20 0.32
TGM2 P21980 1/20 0.32
TGM1 P22735 1/20 0.32
TGM3 Q08188 1/20 0.32
NR1H3 Q13133 2/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
ATM Q13315 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950797 0.84 ALDH1A1 (0.35) MEN1KMT2ANR1H2ALDH1A1GAA
SCHEMBL947189 0.84 NR1H2 (0.42) NR1H2PPARGPPARANR1H3
SCHEMBL5441049 0.82 MEN1 (0.35) MEN1KMT2AALDH1A1GAAF13A1
SCHEMBL949818 0.78 MDM2 (0.34) MEN1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL1384373 0.76 NR1H2 (0.42) MEN1KMT2ANR1H2PPARGPPARA
SCHEMBL949445 0.76 PHGDH (0.41) MEN1KMT2AALDH1A1GAAPPARG
SCHEMBL948084 0.70 F10 (0.50)
SCHEMBL4389624 0.69 AKR1C3 (0.49) MEN1KMT2ANR1H2NR1H3L3MBTL1
SCHEMBL947661 0.69 F10 (0.67)
SCHEMBL5100485 0.69 LMNA (0.39) NR1H2ALDH1A1GAANR1H3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 MEN1 1291/4885KMT2A 417/4885NR1H2 67/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 MEN1 1197/4885KMT2A 491/4885NR1H2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.